Standard

Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches. / Zakharova, Irina; Saaya, Shoraan; Shevchenko, Alexander et al.

In: Frontiers in Bioengineering and Biotechnology, Vol. 10, 772981, 11.03.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

Zakharova, I, Saaya, S, Shevchenko, A, Stupnikova, A, Zhiven', M, Laktionov, P, Stepanova, A, Romashchenko, A, Yanshole, L, Chernonosov, A, Volkov, A, Kizilova, E, Zavjalov, E, Chernyavsky, A, Romanov, A, Karpenko, A & Zakian, S 2022, 'Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches', Frontiers in Bioengineering and Biotechnology, vol. 10, 772981. https://doi.org/10.3389/fbioe.2022.772981

APA

Zakharova, I., Saaya, S., Shevchenko, A., Stupnikova, A., Zhiven', M., Laktionov, P., Stepanova, A., Romashchenko, A., Yanshole, L., Chernonosov, A., Volkov, A., Kizilova, E., Zavjalov, E., Chernyavsky, A., Romanov, A., Karpenko, A., & Zakian, S. (2022). Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches. Frontiers in Bioengineering and Biotechnology, 10, [772981]. https://doi.org/10.3389/fbioe.2022.772981

Vancouver

Zakharova I, Saaya S, Shevchenko A, Stupnikova A, Zhiven' M, Laktionov P et al. Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches. Frontiers in Bioengineering and Biotechnology. 2022 Mar 11;10:772981. doi: 10.3389/fbioe.2022.772981

Author

Zakharova, Irina ; Saaya, Shoraan ; Shevchenko, Alexander et al. / Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches. In: Frontiers in Bioengineering and Biotechnology. 2022 ; Vol. 10.

BibTeX

@article{35d298e94eb2488fb10fa5173a51df08,
title = "Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches",
abstract = "In our previous study, we showed that discarded cardiac tissue from the right atrial appendage and right ventricular myocardium is an available source of functional endothelial and smooth muscle cells for regenerative medicine and tissue engineering. In the study, we aimed to find out what benefits are given by vascular cells from cardiac explants used for seeding on vascular patches engrafted to repair vascular defects in vivo. Additionally, to make the application of these cells safer in regenerative medicine we tested an in vitro approach that arrested mitotic division to avoid the potential tumorigenic effect of dividing cells. A tissue-engineered construction in the form of a patch based on a polycaprolactone-gelatin scaffold and seeded with endothelial and smooth muscle cells was implanted into the abdominal aorta of immunodeficient SCID mice. Aortic patency was assessed using ultrasound, MRI, immunohistochemical and histological staining. Endothelial and smooth muscle cells were treated with mitomycin C at a therapeutic concentration of 10 μg/ml for 2 h with subsequent analysis of cell proliferation and function. The absence of the tumorigenic effect of mitomycin C-treated cells, as well as their angiogenic potential, was examined by injecting them into immunodeficient mice. Cell-containing patches engrafted in the abdominal aorta of immunodeficient mice form the vessel wall loaded with the appropriate cells and extracellular matrix, and do not interfere with normal patency. Endothelial and smooth muscle cells treated with mitomycin C show no tumorigenic effect in the SCID immunodeficient mouse model. During in vitro experiments, we have shown that treatment with mitomycin C does not lead to a decrease in cell viability. Despite the absence of proliferation, mitomycin C-treated vascular cells retain specific cell markers, produce specific extracellular matrix, and demonstrate the ability to stimulate angiogenesis in vivo. We pioneered an approach to arresting cell division with mitomycin C in endothelial and smooth muscle cells from cardiac explant, which prevents the risk of malignancy from dividing cells in vascular surgery. We believe that this approach to the fabrication of tissue-engineered constructs based on mitotically inactivated cells from waste postoperative material may be valuable to bring closer the development of safe cell products for regenerative medicine.",
keywords = "endothelial cells, mitomycin C, polycaprolactone, smooth muscle cells, tissue-engineered vascular graft, vascular patch",
author = "Irina Zakharova and Shoraan Saaya and Alexander Shevchenko and Alena Stupnikova and Maria Zhiven' and Pavel Laktionov and Alena Stepanova and Alexander Romashchenko and Lyudmila Yanshole and Alexander Chernonosov and Alexander Volkov and Elena Kizilova and Evgenii Zavjalov and Alexander Chernyavsky and Alexander Romanov and Andrey Karpenko and Suren Zakian",
note = "Funding Information: The study of cell-seeded vascular patches was carried out within the state assignment of the Ministry of Health of the Russian Federation N: 21032300337-5. Publisher Copyright: Copyright {\textcopyright} 2022 Zakharova, Saaya, Shevchenko, Stupnikova, Zhiven', Laktionov, Stepanova, Romashchenko, Yanshole, Chernonosov, Volkov, Kizilova, Zavjalov, Chernyavsky, Romanov, Karpenko and Zakian.",
year = "2022",
month = mar,
day = "11",
doi = "10.3389/fbioe.2022.772981",
language = "English",
volume = "10",
journal = "Frontiers in Bioengineering and Biotechnology",
issn = "2296-4185",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches

AU - Zakharova, Irina

AU - Saaya, Shoraan

AU - Shevchenko, Alexander

AU - Stupnikova, Alena

AU - Zhiven', Maria

AU - Laktionov, Pavel

AU - Stepanova, Alena

AU - Romashchenko, Alexander

AU - Yanshole, Lyudmila

AU - Chernonosov, Alexander

AU - Volkov, Alexander

AU - Kizilova, Elena

AU - Zavjalov, Evgenii

AU - Chernyavsky, Alexander

AU - Romanov, Alexander

AU - Karpenko, Andrey

AU - Zakian, Suren

N1 - Funding Information: The study of cell-seeded vascular patches was carried out within the state assignment of the Ministry of Health of the Russian Federation N: 21032300337-5. Publisher Copyright: Copyright © 2022 Zakharova, Saaya, Shevchenko, Stupnikova, Zhiven', Laktionov, Stepanova, Romashchenko, Yanshole, Chernonosov, Volkov, Kizilova, Zavjalov, Chernyavsky, Romanov, Karpenko and Zakian.

PY - 2022/3/11

Y1 - 2022/3/11

N2 - In our previous study, we showed that discarded cardiac tissue from the right atrial appendage and right ventricular myocardium is an available source of functional endothelial and smooth muscle cells for regenerative medicine and tissue engineering. In the study, we aimed to find out what benefits are given by vascular cells from cardiac explants used for seeding on vascular patches engrafted to repair vascular defects in vivo. Additionally, to make the application of these cells safer in regenerative medicine we tested an in vitro approach that arrested mitotic division to avoid the potential tumorigenic effect of dividing cells. A tissue-engineered construction in the form of a patch based on a polycaprolactone-gelatin scaffold and seeded with endothelial and smooth muscle cells was implanted into the abdominal aorta of immunodeficient SCID mice. Aortic patency was assessed using ultrasound, MRI, immunohistochemical and histological staining. Endothelial and smooth muscle cells were treated with mitomycin C at a therapeutic concentration of 10 μg/ml for 2 h with subsequent analysis of cell proliferation and function. The absence of the tumorigenic effect of mitomycin C-treated cells, as well as their angiogenic potential, was examined by injecting them into immunodeficient mice. Cell-containing patches engrafted in the abdominal aorta of immunodeficient mice form the vessel wall loaded with the appropriate cells and extracellular matrix, and do not interfere with normal patency. Endothelial and smooth muscle cells treated with mitomycin C show no tumorigenic effect in the SCID immunodeficient mouse model. During in vitro experiments, we have shown that treatment with mitomycin C does not lead to a decrease in cell viability. Despite the absence of proliferation, mitomycin C-treated vascular cells retain specific cell markers, produce specific extracellular matrix, and demonstrate the ability to stimulate angiogenesis in vivo. We pioneered an approach to arresting cell division with mitomycin C in endothelial and smooth muscle cells from cardiac explant, which prevents the risk of malignancy from dividing cells in vascular surgery. We believe that this approach to the fabrication of tissue-engineered constructs based on mitotically inactivated cells from waste postoperative material may be valuable to bring closer the development of safe cell products for regenerative medicine.

AB - In our previous study, we showed that discarded cardiac tissue from the right atrial appendage and right ventricular myocardium is an available source of functional endothelial and smooth muscle cells for regenerative medicine and tissue engineering. In the study, we aimed to find out what benefits are given by vascular cells from cardiac explants used for seeding on vascular patches engrafted to repair vascular defects in vivo. Additionally, to make the application of these cells safer in regenerative medicine we tested an in vitro approach that arrested mitotic division to avoid the potential tumorigenic effect of dividing cells. A tissue-engineered construction in the form of a patch based on a polycaprolactone-gelatin scaffold and seeded with endothelial and smooth muscle cells was implanted into the abdominal aorta of immunodeficient SCID mice. Aortic patency was assessed using ultrasound, MRI, immunohistochemical and histological staining. Endothelial and smooth muscle cells were treated with mitomycin C at a therapeutic concentration of 10 μg/ml for 2 h with subsequent analysis of cell proliferation and function. The absence of the tumorigenic effect of mitomycin C-treated cells, as well as their angiogenic potential, was examined by injecting them into immunodeficient mice. Cell-containing patches engrafted in the abdominal aorta of immunodeficient mice form the vessel wall loaded with the appropriate cells and extracellular matrix, and do not interfere with normal patency. Endothelial and smooth muscle cells treated with mitomycin C show no tumorigenic effect in the SCID immunodeficient mouse model. During in vitro experiments, we have shown that treatment with mitomycin C does not lead to a decrease in cell viability. Despite the absence of proliferation, mitomycin C-treated vascular cells retain specific cell markers, produce specific extracellular matrix, and demonstrate the ability to stimulate angiogenesis in vivo. We pioneered an approach to arresting cell division with mitomycin C in endothelial and smooth muscle cells from cardiac explant, which prevents the risk of malignancy from dividing cells in vascular surgery. We believe that this approach to the fabrication of tissue-engineered constructs based on mitotically inactivated cells from waste postoperative material may be valuable to bring closer the development of safe cell products for regenerative medicine.

KW - endothelial cells

KW - mitomycin C

KW - polycaprolactone

KW - smooth muscle cells

KW - tissue-engineered vascular graft

KW - vascular patch

UR - http://www.scopus.com/inward/record.url?scp=85127629166&partnerID=8YFLogxK

U2 - 10.3389/fbioe.2022.772981

DO - 10.3389/fbioe.2022.772981

M3 - Article

C2 - 35360387

AN - SCOPUS:85127629166

VL - 10

JO - Frontiers in Bioengineering and Biotechnology

JF - Frontiers in Bioengineering and Biotechnology

SN - 2296-4185

M1 - 772981

ER -

ID: 35853677